Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
This is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
Recently, I had the honor of interviewing Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta Ltd. Accellta is introducing a paradigm shift to the stem cell marketplace by quickly, efficiently, and cost-effectively growing massive quantities of clinical grade cells in xeno-free, feeder-free culture. Based in Haifa, Israel, Dr. Angel leads a team of executives and researches who are world-renowned experts at growing stem cells in suspension.
In major news released today, Nano Dimension Ltd. announced it has successfully “lab-tested a proof of concept 3D bioprinter for stem cells” in collaboration with Accellta Ltd. Nano Dimension Ltd. specializes in 3D printing systems, while Accellta uses 3D bioreactors to grow large numbers of cells in suspension. Specifically, Accellta can increase a cell population from 1 million cells to 10 billion cells in two weeks with an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, it would cost of $150,000 and take 40 to 50 days. [Read more…]
This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will address the regulation of stem cells within the United States. [Read more…]
In major news today, Cellect Biomed Ltd. and Accellta announced that they have signed an agreement to evaluate Cellect’s apoptotic induction based technology in combination with Accellta’s stem cell culturing technologies. Cellect Biomed Ltd. is headquartered in Tel Aviv, while Accellta is headquartered in Haifa, Israel.
Accellta is a fascinating stem cell company that can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture, by utilizing methods of growing the cells in suspension. Specifically, the company can increase a cell population from 1 million cells to 10 billion cells in two weeks with a bi-weekly change of media and an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, this would take about 70 liters of medium and an overall cost of $150,000, because it would take 40 to 50 days to do the expansion. [Read more…]